Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 2/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.41 |
| ▸ | VEGFA | P15692 | 2/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | ROS1 | P08922 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257789 | 1.00 | PPID (0.42) | PPIDEGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL24257817 | 0.89 | EGLN1 (0.50) | EGLN1EGLN3VEGFAFLT1CCNC | |
| SCHEMBL30452725 | 0.89 | EGLN1 (0.50) | EGLN1EGLN3VEGFAFLT1CCNC | |
| SCHEMBL30452742 | 0.88 | EGLN1 (0.51) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL24257636 | 0.88 | EGLN1 (0.51) | EGLN1EGLN3VEGFAFLT1FTO | |
| SCHEMBL24257534 | 0.86 | CASP1 (0.49) | PPIDEGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL30453195 | 0.86 | CASP1 (0.49) | PPIDEGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL24257795 | 0.85 | EGLN1 (0.41) | EGLN1EGLN3VEGFAFLT1CASP1 | |
| SCHEMBL30452729 | 0.85 | EGLN1 (0.41) | EGLN1EGLN3VEGFAFLT1CASP1 | |
| SCHEMBL24257545 | 0.84 | ALDH1A1 (0.46) | PPIDEGLN1EGLN3VEGFAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | PPID 1401/4885EGLN1 19/4885EGLN3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.